loader2
Partner With Us NRI

Healthcare Global Enterprises Ltd share Price Today

Company details

333.00
339.95
257.60
401.00
6M Return -4.82%
1Y Return 30.90%
Mkt Cap.(Cr) 4,705.54
Volume 141,660
Div Yield 0.00%
OI
-
OI Chg %
-
Volume 141,660

Open Free Trading Account Online with ICICIDIRECT

Incur '0' Brokerage upto ₹500
Expertise in cancer-care and expansion to the fore…
About The Stock

    HCG operates one of the largest private cancer care networks in India with end-to-end solutions available under a single corporate entity. Most centres are on a lease or rental basis with some in partnership with local doctors or hospitals. Owing to exclusive agreement with vendors, HCG procures equipment on a deferred payment basis. Milann offers seven fertility centres in India.

    • HCG network has 22 comprehensive cancer centres (one in Kenya, four multi-specialty hospitals. HCG India, capacity beds: 1944; 1702 operational
    • Revenue mix FY22: HCG: 96%, Milann:4%; occupancy FY22: 58.3%; ARPOBD FY22: 36,697
Q4FY22

    HCG reported continued momentum this quarter.

    • Sales were up 22% YoY to ₹ 365 crore
    • EBITDA was at ₹ 63 crore, up 57% YoY with margins at 17.3%
    • Consequent adjusted profit for the quarter was at ₹ 6 crore

Click here for full recommendation

Research view on more stocks

Healthcare Global Enterprises announced Q3FY24 & 9MFY24 results:

Financial Performance

  • Revenue: Q3FY24 revenue reached Rs 4,699 million, marking an increase of 11% YoY. Over 9MFY24, the revenue climbed to Rs 14,175 million, reflecting a growth of 13% YoY.
  • Adjusted EBITDA: The company reported an adjusted EBITDA of Rs 826 million for Q3FY24, achieving a 7% rise YoY. For 9MFY24, adjusted EBITDA was Rs 2,455 million, indicating an 8% YoY increase.
  • Profit After Tax: The Profit After Tax (PAT) for Q3FY24 was Rs 57 million, a decrease of 24% YoY. While for 9MFY24, the PAT stood at Rs 269 million.

Revenue Breakup

  • Mature Centers: Q3FY24 revenue from mature centers was 790 million.
  • Emerging Centers: Revenue from emerging centers in Q3FY24 reached 1,015 million.

EBITDA Breakup - Mature vs Emerging Centers

  • Mature Centers: Demonstrated a YoY growth of 19.3%, with an increased revenue of Rs 3,323 million in Q3FY24 compared to Rs 3,065 million in Q3FY23.
  • Emerging Centers: Shown a YoY growth of 65.7%, with a revenue hike from Rs 122 million in Q3FY23 to Rs 126 million in Q3FY24.

Operational KPIs (Oncology)

  • OPD Footfall: Q3FY24 experienced 110,000 footfalls, as compared to 91,000 in Q3FY23.
  • Chemo Sessions Administered: The company administered 36,000 chemo sessions in Q3FY24 whereas it was 34,000 in Q3FY23.
  • LINAC Capacity Utilizations: Utilization increased to 61% in Q3FY24 from 60% in Q3FY23.
  • In-Patient Bed Occupancy: Saw a slight decrease to 52% in Q3FY24 from 57% in the previous year.

Commenting on the results, Dr. B.S. Ajaikumar, Executive Chairman, HealthCare Global Enterprises said, “India is at the cusp of significant demographic change leading to a doubling of population aged over 60 years by 2050. Cancer incidence is expected to increase by 77% during this period. HCG, with its network of 22 Cancer Centers and expansion plans is poised to play a dominant role in serving the diagnostic and treatment needs of the forecasted demand.

HCG's performance for the quarter serves as evidence of its progress in advancing towards focused cancer care, where research and collaboration are the key drivers for improving patient outcomes. By leveraging these unique value propositions, we are able to provide targeted treatments such as adaptive radiotherapy and immunotherapy to our patients. Moreover, our integration of technology into patient care processes, including computational work and Al platforms, allows us to continuously be on the leading edge of the change, creating a differential in the way cancer has evolved.

At HCG, we have always embraced technology and innovation to be at the forefront of advancement in cancer care. We have consistently adopted cutting-edge solutions to ensure that we provide the highest quality healthcare to our patients. Our ability to deeply connect with patients is built on a foundation of compassion and trust that is unmatched, which is what truly sets HCG apart from others in our field. We remain committed to continue making a meaningful difference in the lives of those we serve in making Cancer a chronic disease."

 

Result PDF

View Other Company Results

Healthcare Global Enterprises Ltd shares SWOT Analysis

Strengths (6)

  • Effectively using its capital to generate profit - RoCE improving in last 2 years
  • Company with Low Debt
  • Strong cash generating ability from core business - Improving Cash Flow from operation for last 2 years

Weakness (2)

  • Declining Net Cash Flow : Companies not able to generate net cash
  • Weak Momentum: Price below Short, Medium and Long Term Averages

Opportunity (0)

Data not found

Threats (3)

  • Promoter decreasing their shareholding
  • High PE (PE > 40)
  • Increasing Trend in Non-Core Income

Resistance and support

R1 340.9
R2 343.9
R3 347.8
Pivot

336.93

S1 333.9
S2 330.0
S3 327.0
EMA SMA
343.1
351.7
354.4
345.6
339.4
355.5
360.5
351.5
Delivery and volume
CLIENT NAME DEAL TYPE ACTION DATE AVG. PRICE QUANTITY EXCHANGE
ACESO COMPANY PTE LTD Bulk Purchase 2023-06-01 320 3575000 NSE
B S AJAIKUMAR Bulk Sell 2023-06-01 320 3575000 NSE
ACESO COMPANY PTE LTD Block Purchase 2023-06-01 320 3575000 NSE
Name Category Shares
B S AJAIKUMAR PROMOTER 10.41%
ACESO COMPANY PTE. LTD. PROMOTER 60.41%

OUR RESEARCH VIEW

Investment recommendation
Expertise in cancer-care and expansion to the fore…
Call Date
18 Mar 2024
Entry Price 345.00
Target Price 435.00
Duration
12-18 Month

FINANCIALS

Sales
Operating Profit
Profit after Tax
Equity
Reserves and Surplus
Debt
Sales
Operating Profit
Profit after Tax
PE
Debt/Equity
P BV

Healthcare Global Enterprises Ltd Stocks COMPARISON

Financials( in Cr) Healthcare Global Enterprises Ltd Apollo Hospitals Enterprise Ltd Max Healthcare Institute Ltd Global Health Ltd Fortis Healthcare Ltd
Price 337.85 6,356.80 819.90 1,321.15 420.20
% Change 0.16 2.01 2.19 -1.42 1.69
Mcap Cr 4,705.54 91,401.25 79,680.01 35,463.23 31,723.34
Revenue TTM Cr 1,691.41 16,612.50 4,831.37 2,694.25 6,537.06
Net Profit TTM Cr 17.63 887.50 1,103.51 326.08 632.98
PE TTM 133.68 115.89 75.40 78.65 59.22
1 Year Return 30.90 47.21 78.47 179.11 64.69
ROCE 6.56 14.16 13.85 16.49 7.51
ROE 1.35 15.04 16.12 16.13 6.79
INSIDER & INSTITUIONAL ACTIVITY

Equity Capital: 860.53 Cr FV: 10.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 29,068.81 33,709.58
LAST 3M 68,518.10 30,558.15
LAST 6M 130,081.93 64,349.19
LAST 12M 189,941.35 208,211.24

Healthcare Global Enterprises Ltd Information

Stock PE (TTM)
133.68
Promoter Holding
71.29%
Book Value
61.5839
ROCE
6.56%
ROE
1.35%
Description
  • Healthcare Global Enterprises Ltd is a provider of speciality healthcare in India focused on cancer and fertility. Under the `HCG` brand, it operates the largest cancer care network in India in terms of the total number of private cancer treatment centres licensed by the AERB. As of March 31, 2017, HCG network consisted of 18 comprehensive cancer centres, including its centre of excellence in Bengaluru, three freestanding diagnostic centres and one day care chemotherapy centre across India. Under the `Milann` brand, it operates fertility centres. Milann fertility centres provide comprehensive reproductive medicine services, including assisted reproduction, gynaecological endoscopy and fertility preservation; and follow a multidisciplinary and technology-focused approach to diagnosis and treatment. The Milann network also operates on a model similar to our HCG network, wherein the various Milann fertility centres aim to provide medical services following established protocols with a focus on quality medical care across diagnosis and treatment. The company operates seven Milann fertility centres across Bengaluru, Delhi, Chandigarh and Mumbai as on March 31, 2017. Healthcare Global Enterprises operates two multi-speciality hospitals in Ahmedabad and Bhavnagar, both in the state of Gujarat. HCG Multispecialty in Ahmedabad and Bhavnagar are tertiary care hospitals with 118 and 39 available operational beds, respectively, as of March 31, 2017. It provides comprehensive inpatient and outpatient treatments. Its key specialties include cardiology, neurology, orthopaedics, gastroenterology, urology, internal medicine and pulmonary and critical care. Healthcare Global Enterprises provides clinical reference laboratory services in India under the Triesta brand with a specialisation in oncology, including molecular diagnostic services and genomic testing. It has Triesta central reference laboratory located in its centre of excellence in Bengaluru. The Triesta central reference laboratory is accredited by NABL in India, as well as by CAP for quality assurance of laboratory tests performed. Additionally, Triesta offers research and development services to pharmaceutical and biotechnology companies in the areas of clinical trial management and biomarker discovery and validation. Healthcare Global Enterprises Ltd was originally incorporated as Curie Centre of Oncology Private Limited on March 12, 1998 at Bengaluru, Karnataka, India as a private limited company. The name of the company was subsequently changed to HealthCare Global Enterprises Private Limited on November 14, 2005. Thereafter the company was converted into a public limited company and the name of the company was changed to HealthCare Global Enterprises Limited on July 5, 2006. The company acquired 50.10% equity interest in BACC Healthcare in 2013 which operates fertility centres under the Milann brand, through itself and its wholly-owned subsidiary, DKR Healthcare. HCG EKO Oncology LLP (HCG EKO LLP) HCG EKO LLP was incorporated on May 15, 2015, under the LLP Act as a limited liability partnership firm. HCG EKO LLP is authorised to primarily engage in the business of setting up hospitals at Kolkata with high end linear accelerators, oncology pharmacy and matters incidental and ancillary thereto. HCG (Mauritius) Pvt. Ltd. (HCG Mauritius) was incorporated as a Wholly Owned Subsidiary of the company on May 22, 2015, under the Companies Act, 2001 of Mauritius, as a private limited company. HCG Mauritius is authorised to hold companies which are primarily engaged in the business of treating persons with cancer, carrying on research in the field of oncology and providing various services in the field of oncology. HealthCare Global (Africa) Pvt. Ltd (HCG Africa) was incorporated as a Wholly Owned Subsidiary of the company on May 22, 2015, under the Companies Act, 2001 of Mauritius, as a private limited company. HCG Africa is authorised to engage in the business of treating persons with cancer, carrying on research in the field of oncology and providing various services in the field of oncology and hold companies which are engaged in the same business. Healthcare Global Enterprises entered into a share purchase agreement dated November 23, 2015 with HCG TVH, its erstwhile subsidiary, and Anderson Diagnostics Private Limited. Pursuant to the terms of this agreement, Healthcare Global Enterprises has transferred its entire shareholding in HCG TVH aggregating 51% of the total paid up equity share capital of HCG TVH to Anderson Diagnostics Private Limited for an aggregate consideration of Rs.510,000. Accordingly, HCG TVH has ceased to be the subsidiary of the Company during the Financial Year. During the financial year ended 31 March 2016, Healthcare Global Enterprises transferred its entire shareholding in HealthCare Global (Uganda) Private Limited (`HCG Uganda`), HealthCare Global (Kenya) Private Limited (`HCG Kenya`) and HealthCare Global (Tanzania) Private Limited (`HCG Tanzania`) to HealthCare Global (Africa) Pvt. Ltd. Accordingly, HCG Uganda, HCG Kenya and HCG Tanzania have become level two subsidiaries of the company. During the year under review, Healthcare Global Enterprises introduced two major latest technologies at some of its centres viz. Robotic Surgery and Tomotherapy Treatment System. Robotic Surgery is an advanced form of minimally invasive or laparoscopic (small incision) surgery, where surgeons use a computer-controlled robot to assist them in certain surgical procedures. This facility was installed at Bangalore and Ahmedabad centres. The TomoTherapy treatment system uses a patented multi-leaf collimator (MLC) that divides the radiation beam into beamlets, all aimed at the tumor. More beam directions give physicians more control in how they plan treatments-and more assurance that dose will be confined to the tumor, reducing the risk of short- and long-term side effects. This facility was installed at Kalinga Rao Road centre, Bangalore. During the financial year ended 31 March 2016, the company completed its Initial Public Offering (IPO) of 29,800,000 equity shares of Rs. 10 each, comprising of Fresh Issue of 11,600,000 equity shares and Offer For Sale of 18,200,000 equity shares at a premium of Rs. 208 per equity share. The total issue size was Rs. 6496.4 million. The IPO was open for subscription during the period from 16 to 18 March 2016. The shares got listed the National Stock Exchange of India Limited and BSE Limited on 30 March 2016. In April 2016, HCG launched its first cancer centre in Visakhapatnam, under its subsidiary company, HCG Pinnacle Oncology Private Limited. HCG Pinnacle Cancer Centre has a capacity of upto 88 beds and provides high quality and comprehensive cancer care services. In May 2016, the company launched its new advanced comprehensive cancer centre in Baroda, under its subsidiary, HCG Oncology LLP. The Centre has a bed capacity of 65 beds and is one of the most advanced in terms of technology in the HCG network. HCG Manavata Oncology LLP was incorporated on August 10, 2016, under The Limited Liability Partnership Act, 2008 as a limited liability partnership firm. The Partners of the LLP are HCG and Dr. Rajnish Nagarkar, in the capital contribution ratio of 51:49, respectively. HCG Manavata Oncology LLP is authorised to primarily engage in the business of setting up hospitals at Nashik, Maharashtra with high end linear accelerators, pharmacy and matters incidental and ancillary thereto. In March 2017, HCG expanded its operations in Nashik. HCG through its subsidiary HCG Kenya signed definitive agreements in March 2017 to acquire a majority stake in Cancer Care Kenya (CCK) a leading cancer care centre in Nairobi, Kenya, subject to review and approval by the Competition Authority of Kenya (CAK) and other requisite approvals. CDC, the development finance institution of UK Government, which has partnered with HCG for Africa investments, would partner with HCG through HCG Kenya, an off-shore subsidiary, for the acquisition. MP Shah Hospital, a leading tertiary care hospital in Kenya, will also participate in the transaction. CCK, which started operations in 2010, is the first comprehensive cancer centre in Kenya. CCK treats over a thousand patients annually including over two hundred patients from other African nations. During the year ended 31 March 207, the percentage of holding of Healthcare Global Enterprises Ltd in HCG NCHRI Oncology LLP increased from 51% to 76%.In May 2017, HCG launched its first cancer centre in Kanpur, the largest the state of Uttar Pradesh, under its subsidiary company, HCG Regency Oncology Healthcare Private Limited. HCG Regency Oncology Centre is equipped with 90 beds and features advanced radiation therapy, a multi-disciplinary team of oncologists including sub-specialists, as well as the first PET-CT and bone marrow transplant unit.

Registered Address

HCG Tower No 8 Kalinga Rao Rd, Sampangi Rama Nagar, Bangalore, Karnataka, 560027

Tel : 91-80-4660-7700
Email : investors:hcgoncology.com; info:hcgoncology.com
Website : http://www.hcgel.com
Registrar

KFin Techologies Ltd

AGM Date (Month) : Sep
Face Value Equity Shares : 10
Market Lot Equity Shares : 1
BSE Code : 539787
NSE Code : HCG
Book Closure Date (Month) :
BSE Group : B
ISIN : INE075I01017

FAQ’s on Healthcare Global Enterprises Ltd Shares

You can buy Healthcare Global Enterprises Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Healthcare Global Enterprises Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of Mar 28, 2024 03:57 PM the closing price of Healthcare Global Enterprises Ltd was ₹ 337.85.

Market capitalization or market cap is determined by multiplying the current market price of a company’s shares with the total number of shares outstanding. As of Mar 28, 2024 03:57 PM, the market cap of Healthcare Global Enterprises Ltd stood at ₹ 4,705.54.

The latest PE ratio of Healthcare Global Enterprises Ltd as of Mar 28, 2024 03:57 PM is 133.68

The latest PB ratio of Healthcare Global Enterprises Ltd as of Mar 28, 2024 03:57 PM is 0.18

The 52-week high of Healthcare Global Enterprises Ltd share price is ₹ 401.00 while the 52-week low is ₹ 257.60

According to analyst recommendations, Healthcare Global Enterprises Ltd Share has a “Buy” rating for the long term.

Download Our

Download App
market app